Boehringer Ingelheim and Gubra Launch Phase 1 Study of BI 3034701, a Promising Triple Agonist Peptide for Obesity Treatment
Boehringer Ingelheim, a renowned biopharmaceutical firm committed to research, and Gubra have initiated a phase 1 clinical trial (NCT06352437) for BI 3034701, a novel long-acting triple agonist peptide aimed at revolutionizing obesity treatment.
Obesity affects over 1 billion people globally, a number expected to rise, with projections indicating that by 2035, 24% of the world population will grapple with this disease. Obesity significantly increases the risk of cardiovascular, renal, metabolic diseases, and various cancers, making it a leading cause of global mortality. BI 3034701 represents Boehringer Ingelheim’s commitment to expanding their pipeline beyond weight loss solutions to improve cardiovascular, renal, and metabolic health outcomes for individuals living with obesity.
Søren Tullin, Senior Vice President and Global Head of Cardiometabolic Diseases Research at Boehringer Ingelheim, emphasized, “This phase 1 study marks another milestone in our strategy to enhance the quality and longevity of lives affected by interconnected cardiovascular, renal, and metabolic diseases.”
Henrik Blou, CEO of Gubra, echoed this sentiment, stating, “We are thrilled to advance BI 3034701 into phase 1 clinical trials. With the global prevalence of obesity on the rise, there is a critical need for innovative treatments like this triple agonist, which targets receptors known to promote weight loss.”
BI 3034701 was developed in collaboration with Gubra, leveraging Gubra’s licensed intellectual property, while Boehringer Ingelheim assumes sole responsibility for global development and commercialization. This collaboration follows the successful phase 1 clinical outcomes of BI 1820237 announced in 2023.
The phase 1 trial is a randomized, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of BI 3034701. The trial consists of two parts: Part A involves healthy men aged 18 to 55, while Part B includes individuals aged 18 to 65 with overweight or obesity who are otherwise healthy. Participants receive varying doses of BI 3034701 or placebo via subcutaneous injection. Part A participants receive a single dose, while Part B participants receive multiple doses. This study marks the first administration of BI 3034701 to humans and is anticipated to conclude in the latter half of 2025, involving approximately 124 participants.
The initiation of the phase 1 trial triggers a milestone payment to Gubra, underscoring the progress of their collaborative efforts.
Boehringer Ingelheim remains dedicated to pioneering therapies that significantly impact lives today and for future generations. As a leading research-driven biopharmaceutical company, Boehringer Ingelheim focuses on innovation in areas with substantial unmet medical needs.
Gubra, founded in Denmark in 2008 and listed on Nasdaq Copenhagen in 2023, specializes in pre-clinical contract research services and peptide-based drug discovery, particularly in metabolic and fibrotic diseases.